David Cory, Eiger BioPharmaceuticals CEO (Eiger via MultiVu)

A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

The big hey­day of mar­ket delir­i­um re­lat­ed to any­thing pos­i­tive in new Covid-re­lat­ed da­ta has pe­tered out as Omi­cron pass­es over, but lit­tle Eiger Bio­Phar­ma­ceu­ti­cals did get a quick pop-up in the stock price $EIGR this morn­ing af­ter re­port­ing some up­beat re­sults from its Phase III study of pe­gy­lat­ed in­ter­fer­on lamb­da.

Eiger says it’s beat­ing a path to the FDA to see about a snap emer­gency use au­tho­riza­tion for its treat­ment af­ter gath­er­ing late-stage da­ta from close to 2,000 pa­tients — 84% of whom had at least one vac­ci­na­tion against Covid.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.